Physician profile
Sheetal Bhaga
NPI 1538356365
$9,004.77
in general payments reported to CMS, 2019-2025
16 companies · $4,445 in 2025
The $4,445 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $310 · 2021: $478 · 2022: $1,202 · 2023: $1,026 · 2024: $599 · 2025: $4,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $2,552 · Travel and Lodging: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $2,552.11 |
| Travel and Lodging | $518.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $4,615.13 | 2019-2025 | Biofinity Contact Lens, Myday Contact Lens, Cvi Contact Lens |
| Alcon Vision LLC | $1,532.43 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Biotissue Holdings INC. | $944.06 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $551.75 | 2022-2025 | Infuse |
| Abbvie INC. | $253.10 | 2022-2023 | Lumigan |
| Johnson & Johnson Vision Care, INC. | $216.91 | 2022-2023 | Acuvue |
| Dompe US, INC. | $148.76 | 2024-2025 | Oxervate |
| Maculogix, INC. | $140.65 | 2019 | |
| Sun Pharmaceutical Industries INC. | $123.01 | 2020-2022 | |
| Genzyme Corporation | $121.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $118.77 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $96.92 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.39 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $29.64 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.76 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Bhaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.